Exploring the Mechanism, Promise, and Research Behind This Selective Anti-Cancer Agent

Researched and written by Keith Bishop, Clinical Nutritionist, Cancer Coach, Retired Pharmacist, and Founder of Prevail Over Cancer

PNC-27 and Cancer Introduction

PNC-27 is an investigational anticancer peptide derived from the tumor suppressor protein p53. Unlike conventional chemotherapeutics that broadly target dividing cells, PNC-27 selectively binds to cancer cells expressing HDM-2 (also known as MDM2) on their outer membranes. This unique mechanism has sparked interest in its potential to induce rapid, necrotic cell death while sparing healthy tissue. Though not FDA-approved, PNC-27 represents a novel class of membrane-targeting peptides with implications for integrative oncology and terrain-based care.

PNC-27 Cancer Mechanism of Action

PNC-27 contains a p53-derived binding domain that targets HDM-2, a protein overexpressed on the surface of many cancer cells. Upon binding, PNC-27 inser...